Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oxybutynin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44354   clinical trials with a EudraCT protocol, of which   7381   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Oxybutynin. Displaying page 1 of 1.
    EudraCT Number: 2019-004417-13 Sponsor Protocol Number: CHUBX2018/65 Start Date*: 2020-06-02
    Sponsor Name:CHU de Bordeaux
    Full Title: PROSPECTIVE RANDOMIZED CLINICAL TRIAL OF EARLY OXYBUTININ TREATMENT FOR BOYS WITH POSTERIOR URETHRAL VALVES
    Medical condition: POSTERIOR URETHRAL VALVES
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003929-30 Sponsor Protocol Number: 1 Start Date*: 2022-10-14
    Sponsor Name:Ligalli BV
    Full Title: INFLUENCE OF OXYBUTYNIN - MEDRING LIGALLI ON OVERACTIVE BLADDER SYMPTOMS IN WOMEN
    Medical condition: urinary urge incontinence
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005523-42 Sponsor Protocol Number: 905-EC-005 Start Date*: 2007-09-05
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A randomized, double blind, double dummy, placebo controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10mg once daily) against placebo and oxybutynin hydrochloride ...
    Medical condition: Neurogenic detrusor overactivity.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) NL (Completed) GB (Completed) HU (Completed) FR (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-005009-41 Sponsor Protocol Number: 05WH25 Start Date*: 2006-01-11
    Sponsor Name:King's College Hospital
    Full Title: Warning Time and Patient-Selected Goals: A Placebo Controlled Randomised Double-Blind Pilot Study of the Efficacy of Transdermal Oxybutynin for the Treatment of Urgency and Urge Incontinence.
    Medical condition: Overactive bladder.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-007053-13 Sponsor Protocol Number: STEG-CORP_111802 Start Date*: 2009-07-31
    Sponsor Name:Grachtenhaus-Apotheke, Inh. Klaus Stegemann e. K.
    Full Title: Doppelblinde, randomisierte, Placebo-kontrollierte Studie der Phase III zur Bestimmung der Wirksamkeit, Verträglichkeit und Sicherheit von intravesikal verabreichter Oxybutynin-Lösung bei Kindern/J...
    Medical condition: bladder disorder (detrusor hyperactivity caused by neurogenic disorder)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061011 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001250-24 Sponsor Protocol Number: 850 1016-1562 Start Date*: 2005-08-16
    Sponsor Name:APOGEPHA Arzneimittel GmbH
    Full Title: Proof-of-Concept Trial of NS-8 in 3 doses: Comparison of efficacy and tolerability in patients with overactive bladder.
    Medical condition: Subjects with overactive bladder syndrome with urinary urge.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000475-16 Sponsor Protocol Number: 2006-001-Oxy-OAB-Skin-Oxy Start Date*: 2007-04-12
    Sponsor Name:Johannes Gutenberg-Universität Mainz, Urologische Klinik (ausführende Stelle), Prof. Dr. med. Thürof
    Full Title: Prospective, randomized, open, crossover, patient preference study comparing oral immediate release and transdermal oxybutynin in overactive bladder patients
    Medical condition: •Male or female (18 – 80 years) suffering from OAB. •Symptoms of OAB as defined by: Urgency frequency ≥7 /week,•Urinary urgency incontinence (≥ 7 UIE/week),•Urodynamically proven detrusor instability
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004654-81 Sponsor Protocol Number: DL06001/02 Start Date*: 2007-12-20
    Sponsor Name:Summit (Cambridge) Ltd.
    Full Title: A phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a combination treatment for reducing saliva secretion in Parkinson’s disease patients
    Medical condition: Sialorrhoea associated with Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059812 Sialorrhoea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005295-33 Sponsor Protocol Number: S54913 Start Date*: 2013-03-08
    Sponsor Name:UZ Leuven-Department of Urology
    Full Title: Monocentric, open-label, phase III study that compares the efficiency and tolerance between intravesical oxybutynin and oral fesoterodine in children (5-16y) with neurogenic detrusor overactivity.
    Medical condition: children with neurogenic detrusor overactivity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10041524 Spina bifida PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011843-38 Sponsor Protocol Number: STEG-CORP_111804 Start Date*: 2009-12-07
    Sponsor Name:Grachtenhaus-Apotheke, Inh. Klaus Stegemann e.K.
    Full Title: Documentation of the efficacy and tolerability of intravesically applied oxybutynin solution in adult patients with detrusor hyperactivity caused by neurological disorder
    Medical condition: Detrusor hyperactivity caused by neurological dysfunction
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10061011 Bladder disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022475-55 Sponsor Protocol Number: A0221047 Start Date*: 2012-07-20
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A 24-WEEK RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 17 YEARS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDI...
    Medical condition: Neurogenic Detrusor Overactivity (NDO).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10029279 Neurogenic bladder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) EE (Completed) FI (Completed) SK (Completed) GB (Completed) ES (Completed) GR (Completed) FR (Completed) NL (Completed) BE (Completed) RO (Ongoing) DK (Prematurely Ended) DE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004917-15 Sponsor Protocol Number: RebOx Start Date*: 2020-04-22
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Crossover, Double-blind, Phase 2 Study of a Fixed Dose Combination of Reboxetine\Oxybutynin (AD128) Versus Placebo in Obstructive Sleep Apnea (RebOx)
    Medical condition: Obstructive Sleep Apnea
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10040978 Sleep apnoeas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000711-24 Sponsor Protocol Number: 2013-000711-24 Start Date*: 2013-10-09
    Sponsor Name:Søren Rittig
    Full Title: The effect of combining anticholinergic treatment and transcutaneous electrical nerve stimulation in children suffering from daytime urinary incontinence and an overactive bladder.
    Medical condition: Daytime urinary incontinence and overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002157-51 Sponsor Protocol Number: 1034-PhII Start Date*: 2005-08-03
    Sponsor Name:Antares Pharma AG
    Full Title: A Phase II, Single-Center, Open-Label, Parallel, Three-Treatment, Single-Period, Randomized, Single and Multiple-Dose Pharmacokinetic Study of Oxybutynin Gel in Healthy Volunteers
    Medical condition: Study design according to CPMP/EWP/QWP/1401/98 and CPMP/EWP/280/96. Using an open-label, three-treatment, dose-ranging, single-period, randomized, single and multiple-dose design, three treatments ...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012378 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2023-000062-34 Sponsor Protocol Number: Reb-Oxy-OSA Start Date*: 2023-06-02
    Sponsor Name:CHU Brugmann
    Full Title: Combination of Reboxetine 4mg and Oxybutynin 5mg for treating moderate obstructive sleep apnea: a one-month randomized placebo-controlled double-blind study
    Medical condition: Obstructive sleep apnea
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004855 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001068-36 Sponsor Protocol Number: R03465 Start Date*: 2014-10-22
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: Onabotulinum toxin-A versus extended release tolterodine in the management of idiopathic overactive bladder in children: A pilot randomised controlled trial (OVERT)
    Medical condition: Idiopathic Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Aug 14 21:29:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA